Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05390515 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Psoriatic Immune Response to Tildrakizumab

StatusRecruiting
PhasePhase 4
Started2022-09-01
View on ClinicalTrials.gov ↗

Amendment history

2026-06-01
Study Status v2
Primary completion date2025-09-01→2028-09-01
Completion date2025-09-01→2028-09-01
2023-08-25
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Study sitesdetails revised at 1 of 1 site
2022-05-20
Original filing
This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.
Trial Details
NCT Number NCT05390515
Lead Sponsor University of California, San Francisco
Collaborators: Sun Pharmaceutical Industries Limited
Conditions Psoriasis Vulgaris
Enrollment 10 participants
Start Date 2022-09-01
Primary Completion 2028-09-01 (estimated)
Study Completion 2028-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-04